Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Feb 2026: Roche Diagnostics proposed up to 50 job cuts (about 3% of staff) at its Spanish headquarters in Sant Cugat, reportedly agreed with the works council; the company said it periodically reviews its structure to stay competitive.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving Roche Diagnostics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Nov 2025: Roche began an FDA Class 2 recall of Elecsys Anti-TSHR assay lots over result variability that could delay or mislead diagnosis. Apr 2026: a Class 2 recall of navify Digital Pathology v2.5 followed complaints that images could be linked to the wrong specimen labels.
Contract delivery, go-lives, terminations and disputes.
No contract disputes, terminations or notable NHS/UK contract events involving Roche Diagnostics found in HSH's search of the last 24 months.